Rocket Pharmaceuticals Total Debt vs. EBITDA
| RCKT Stock | USD 13.51 0.33 2.38% |
For Rocket Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rocket Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rocket Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rocket Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rocket Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rocket |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rocket Pharmaceuticals. If investors know Rocket will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rocket Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.73) | Return On Assets (0.34) | Return On Equity (0.59) |
The market value of Rocket Pharmaceuticals is measured differently than its book value, which is the value of Rocket that is recorded on the company's balance sheet. Investors also form their own opinion of Rocket Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rocket Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rocket Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rocket Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rocket Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rocket Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rocket Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rocket Pharmaceuticals EBITDA vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rocket Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rocket Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rocket Pharmaceuticals is rated below average in total debt category among its peers. It is rated below average in ebitda category among its peers . At this time, Rocket Pharmaceuticals' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rocket Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Rocket Total Debt vs. Competition
Rocket Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 1.79 Billion. Rocket Pharmaceuticals claims roughly 25.04 Million in total debt contributing just under 2% to equities under Health Care industry.
Rocket EBITDA vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Rocket Pharmaceuticals |
| = | 25.04 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Rocket Pharmaceuticals |
| = | (236.62 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Rocket EBITDA Comparison
Rocket Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Rocket Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rocket Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rocket Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rocket Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rocket Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 319 K | 334.9 K | |
| Operating Income | -259.7 M | -246.7 M | |
| Income Before Tax | -245.6 M | -233.3 M | |
| Total Other Income Expense Net | 14.1 M | 14.8 M | |
| Net Loss | -245.6 M | -233.3 M | |
| Income Tax Expense | -245.6 M | -233.3 M | |
| Net Loss | -252.7 M | -240 M | |
| Net Loss | -199.7 M | -189.7 M | |
| Non Operating Income Net Other | 179.4 K | 188.4 K | |
| Net Interest Income | 12.3 M | 12.9 M | |
| Interest Income | 13.1 M | 13.7 M | |
| Change To Netincome | 36.1 M | 25.4 M | |
| Net Loss | (2.92) | (3.07) | |
| Income Quality | 0.79 | 0.87 | |
| Net Income Per E B T | 1.14 | 1.13 |
Rocket Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rocket Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rocket Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rocket Pharmaceuticals' important profitability drivers and their relationship over time.
Use Rocket Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rocket Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rocket Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Rocket Pharmaceuticals Pair Trading
Rocket Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Rocket Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rocket Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rocket Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rocket Pharmaceuticals to buy it.
The correlation of Rocket Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rocket Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rocket Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rocket Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rocket Pharmaceuticals position
In addition to having Rocket Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Natural Foods Thematic Idea Now
Natural Foods
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.